Eftekhar Maryam, Mirzaei Maryam, Mangoli Esmat, Mehrolhasani Yasamin
Department of Obstetrics and Gynecology, Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Department of Obstetrics and Gynecology, Jiroft University of Medical Sciences, Jiroft, Kerman, Iran.
Int J Reprod Biomed. 2021 Aug 16;19(7):645-652. doi: 10.18502/ijrm.v19i7.9475. eCollection 2021 Jul.
The effect of adding gonadotropin-releasing hormone (GnRH) agonist on the luteal phase support in assisted reproductive technique (ART) cycles is controversial.
To determine the effects of adding multiple doses of GnRH agonist to the routine luteal phase support on ART cycle outcomes.
This clinical trial study included 200 participants who underwent the antagonist protocol at the Research and Clinical Center for Infertility, Yazd, Iran, between January and March 2020. Of the 200, 168 cases who met the inclusion criteria were equally divided into two groups - the case and the control groups. Both groups received progesterone in the luteal phase, following which the case group received GnRH agonist subcutaneously (0/1 mg triptorelin) zero, three, and six days after the fresh embryo transfer, while the control group did not receive anything. Finally, chemical and clinical pregnancy rates, number of mature oocytes, fertilization rate, total dose of gonadotropin, and the estradiol level were determined.
The baseline characteristics were similar in both groups. No significant difference was observed between embryo transfer cycles. Clinical results showed that differences between the fertilization rate, chemical and clinical pregnancies were not significant.
The results showed that receiving multiple doses of GnRH agonist in the luteal phase of ART cycles neither improves embryo implantation nor the pregnancy rates; therefore, further studies are required.
在辅助生殖技术（ART）周期中添加促性腺激素释放激素（GnRH）激动剂对黄体期支持的效果存在争议。
确定在ART周期的常规黄体期支持中添加多剂量GnRH激动剂对ART周期结局的影响。
这项临床试验研究纳入了2020年1月至3月期间在伊朗亚兹德不孕不育研究与临床中心接受拮抗剂方案的200名参与者。在这200人中，168例符合纳入标准的病例被平均分为两组——病例组和对照组。两组在黄体期均接受黄体酮治疗，之后病例组在新鲜胚胎移植后第0、3和6天皮下注射GnRH激动剂（0.1mg曲普瑞林），而对照组未接受任何治疗。最后，测定化学妊娠率和临床妊娠率、成熟卵母细胞数量、受精率、促性腺激素总剂量以及雌二醇水平。
两组的基线特征相似。胚胎移植周期之间未观察到显著差异。临床结果表明，受精率、化学妊娠和临床妊娠之间的差异不显著。
结果表明，在ART周期的黄体期接受多剂量GnRH激动剂既不能提高胚胎着床率，也不能提高妊娠率；因此，需要进一步研究。
